Litigation Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

Docket		Date Filed	2015-02-20
Court	District Court, D. New Jersey	Date Terminated	2017-04-11
Cause	15:1126 Patent Infringement	Assigned To	Esther Salas
Jury Demand	None	Referred To	Joseph A. Dickson
Parties	ROXANE LABORATORIES, INC.
Patents	6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275; 8,859,619; 8,952,062
Attorneys	WILLIAM C. BATON
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-20				External link to document
2015-02-19	63		SCHEDULING ORDER FOR U.S. PATENT NOS. 8,461,203, 8,859,619, AND 8,952,062: that the deadline for… SCHEDULING ORDER FOR U.S. PATENT NOS. 8,461,203, 8,859,619, AND 8,952,062 THIS MATTER…302 patents be consolidated into this action should the Patent and Trademark Office's Patent Trial…'062 patents 1: The parties agreed that proceedings relating to U.S. Patent Nos. 8,77,306…2015 11 April 2017 2:15-cv-01360 830 Patent None District Court, D. New Jersey	External link to document
2015-02-19	83		of U.S. Patent Nos. 8,461,203 (“the ‘203 patent”), 8,772,306 (“the ‘306 patent”), 8,859,619 (“the ‘619…‘619 patent”), 8,952,062 (“the ‘062 patent”), and 9,050,302 (“the ‘302 patent”) (collectively, “patents-in-suit…, ‘619, and ‘062 patents are part of the family of patents derived from U.S. Patent No. 6,472,431 (“the…and ‘302 patents as “the DDI patents”). Of the 121 asserted claims in these five patents, the parties…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history	External link to document
2015-02-19	84		6,780,889, 7,262,219, 7,851,506, 8,263,650, and 8,324,275. …The other patents in the ’431 patent family are U.S. Patent Nos. 6,472,431 (“the ’431 patent”), 6,780,…of United States Patent Nos. 8,461,203 (“the ’203 patent”), 8,859,619 (“the ’619 patent”), and 8,952,062…the ’062 patent”) (collectively, the “’431 patent family”), and 8,772,306 (“the ’306 patent”) and 9,050,302…’302 patent”) (collectively, the “’306 patent family”) owned by Jazz (collectively, “the patents-in-suit	External link to document

Jazz Pharmaceuticals v. Roxane Laboratories, 2:15-cv-01360: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., C.A. No. 2:15-cv-01360, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Roxane’s proposed generic version of Xyrem, Jazz’s sodium oxybate product for narcolepsy. Jazz asserted patents covering Xyrem’s restricted-distribution system and related methods of administration. The case ended without a reported trial judgment on infringement or validity after the parties resolved the dispute through a confidential settlement and dismissal.

What was Jazz Pharmaceuticals v. Roxane Laboratories about?

The dispute arose after Roxane filed an Abbreviated New Drug Application, or ANDA, seeking FDA approval to market generic sodium oxybate oral solution. Jazz treated Roxane’s ANDA filing as a Paragraph IV certification challenging patents listed for Xyrem in the FDA’s Orange Book.

Jazz filed suit under the Hatch-Waxman Act. The lawsuit triggered the statutory 30-month stay of FDA approval applicable to the challenged ANDA, subject to statutory exceptions and court developments.

Item	Case detail
Plaintiff	Jazz Pharmaceuticals, Inc.
Defendant	Roxane Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	2:15-cv-01360
Product	Xyrem, sodium oxybate oral solution
Regulatory pathway	ANDA under the Hatch-Waxman Act
Dispute type	Paragraph IV patent challenge
Core technology	Controlled distribution, restricted access, and safe-use methods
Disposition	Settlement and dismissal
Trial judgment	No reported final merits judgment in the public docket

The case was part of a broader series of Xyrem patent disputes involving generic-drug companies that challenged Jazz’s Orange Book-listed patents.

What patents protected Xyrem in the Roxane litigation?

The Roxane case focused on patents associated with Xyrem’s controlled-distribution system and administration methods rather than a conventional small-molecule composition patent alone. Public patent records and related Xyrem litigation identify the following patent families as commercially relevant to the dispute:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 8,731,963	Restricted distribution and controlled access for sodium oxybate	Protected elements of Xyrem’s risk-management and dispensing system
U.S. Patent No. 8,772,306	System and method for controlled distribution	Addressed distribution controls and pharmacy access
U.S. Patent No. 6,780,889	Sodium oxybate formulations and related pharmaceutical use	Earlier foundational Xyrem patent
U.S. Patent No. 7,668,730	Treatment and administration of sodium oxybate	Method-of-use protection
U.S. Patent No. 8,263,650	Administration and dosing-related methods	Supplemental method-of-use protection

The exact claims asserted against Roxane must be determined from the complaint, infringement contentions, claim-construction record, and final settlement-related docket entries. Public summaries of the case generally identify Jazz’s controlled-distribution patents as the central dispute.

Patent expiration dates varied by patent, patent-term adjustment, pediatric exclusivity, and any terminal disclaimers. For this reason, the nominal expiration date of a patent number should not be treated as the effective generic-entry date without checking the Orange Book and FDA regulatory records.

What was the FDA and Orange Book status of Xyrem?

Xyrem is an FDA-approved sodium oxybate oral solution marketed by Jazz for cataplexy or excessive daytime sleepiness in patients with narcolepsy. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate, or GHB, a controlled substance with abuse and misuse risks.

Jazz’s commercial protection combined several layers:

1. FDA regulatory exclusivity for the approved product and indications.
2. Orange Book-listed patents.
3. Patent litigation against ANDA filers.
4. A proprietary restricted-distribution system.
5. Manufacturing, quality-control, and controlled-substance compliance requirements.

Xyrem was subject to an FDA-mandated risk evaluation and mitigation strategy, or REMS. The risk controls limited distribution through certified pharmacies and imposed prescribing, dispensing, and patient-monitoring requirements. Jazz also maintained a single-pharmacy distribution model for Xyrem during the relevant litigation period.

The REMS and distribution system were important commercial assets, but they did not independently create patent protection. The patents had to cover the claimed system, method, or technical steps, and Jazz had to establish infringement based on the proposed generic product and its associated distribution processes.

When did Roxane challenge Xyrem patents under Paragraph IV?

Roxane’s ANDA filing led Jazz to assert patent rights under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA seeking approval before patent expiration as an act of infringement for purposes of resolving the patent dispute before commercial launch.

A Paragraph IV certification generally alleges that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The certification gives the brand company a basis to file suit and seek the Hatch-Waxman 30-month stay.

The litigation therefore concerned an anticipated future generic product rather than an already marketed Roxane product. The core legal questions would have included:

• Whether Roxane’s proposed sodium oxybate product fell within the asserted patent claims.
• Whether Jazz’s asserted claims were valid over prior art.
• Whether any claims were indefinite or inadequately supported.
• Whether Jazz could prove infringement of system or method claims based on Roxane’s proposed labeling and distribution arrangements.
• Whether claim elements involving a pharmacy, prescriber, patient, or distributor created divided-infringement issues.

What was the litigation timeline?

The public case chronology can be summarized as follows:

Date or period	Event
2015	Roxane filed an ANDA seeking approval for generic sodium oxybate; Jazz filed the patent infringement action in Delaware
2015-2016	Pleadings, jurisdictional matters, and discovery proceeded
2016-2017	The parties litigated patent issues involving Xyrem’s distribution and use patents
2017	Jazz and Roxane resolved the dispute through a settlement
After settlement	The action was dismissed pursuant to the parties’ agreement
2023	FDA approvals and commercial activity involving generic sodium oxybate increased after key Xyrem market protections weakened

The docket does not establish a final court finding that Roxane infringed the asserted patents. It also does not establish that the patents were invalid. The commercial result came from settlement rather than a reported merits decision.

What was the outcome of the Roxane settlement?

Jazz and Roxane settled the case, and the action was dismissed. The settlement terms were not publicly disclosed in the ordinary docket record.

The public record does not support treating the settlement as:

• An adjudication that the asserted patents were valid.
• An adjudication that Roxane’s ANDA infringed.
• A judicial determination that Roxane had a right to launch on a specified date.
• A finding that Jazz’s REMS-related patent estate was enforceable.

Confidential Hatch-Waxman settlements commonly include provisions addressing the earliest permissible generic launch date, patent challenges, supply arrangements, or other commercial rights. Unless the agreement or an associated FTC filing is public, the exact entry date and payment terms cannot be inferred from dismissal alone.

The settlement reduced immediate litigation risk for Jazz and provided Roxane with a negotiated resolution. It did not eliminate later challenges by other generic applicants or determine the validity of the broader Xyrem patent estate.

Did the case involve biosimilar risk?

No. The case involved a generic small-molecule drug, not a biosimilar.

Sodium oxybate is a chemically defined active pharmaceutical ingredient regulated through the ANDA pathway. Biosimilar approval under the Public Health Service Act applies to biological products and is not the relevant regulatory framework for Xyrem.

The competitive risk was therefore generic substitution, Paragraph IV litigation, and possible authorized-generic competition. Key regulatory concepts included ANDA approval, therapeutic equivalence, Orange Book patents, and the Hatch-Waxman litigation stay.

How strong was Jazz’s patent estate in the Roxane case?

Jazz’s patent position was commercially meaningful but legally complex.

Strengths

Jazz had multiple layers of protection around Xyrem:

• Early composition and formulation patents.
• Method-of-use patents directed to narcolepsy treatment.
• Later patents directed to restricted distribution and controlled access.
• A regulated distribution system that made generic substitution operationally difficult.
• Significant product revenue exposure, increasing the value of settlement leverage.

The distribution patents were particularly important because they extended protection beyond the basic active ingredient. They attempted to protect the operational architecture used to prescribe, dispense, and monitor sodium oxybate.

Weaknesses

The estate also faced material litigation risks:

• Older patents had limited remaining life.
• Distribution claims could create divided-infringement issues.
• Prior-art challenges could target known controlled-substance dispensing systems.
• The proposed generic’s labeling and pharmacy arrangements could differ from Jazz’s commercial implementation.
• Method-of-use claims could be vulnerable if the generic label omitted or carved out protected indications.
• A settlement prevented a judicial ruling confirming the validity and enforceability of the asserted claims.

The proper commercial characterization is a layered but contested patent estate. The Roxane settlement preserved near-term commercial protection but did not establish broad, durable exclusivity across every Xyrem patent family.

What litigation risks affected generic launch?

A generic sodium oxybate launch faced several distinct risks.

Patent infringement risk

The ANDA filer risked liability under Section 271(e)(2) before launch and conventional infringement liability after launch. The risk depended on the specific claims, proposed label, formulation, distribution system, and launch date.

Labeling risk

Jazz could argue that a proposed label induced infringement of method-of-use claims. Generic companies often attempt to avoid this exposure through a Section viii statement or a label carve-out, but that strategy depends on whether the patented use can be removed without making the product commercially or regulatorily defective.

Distribution-system risk

Xyrem’s controlled-distribution model complicated infringement analysis. Claims requiring actions by multiple parties can raise questions about direction or control, joint enterprise, or induced infringement. These issues were especially relevant to patents covering pharmacy certification, prescriber registration, patient enrollment, and controlled dispensing.

Regulatory and operational risk

A generic sponsor also had to establish:

• FDA-acceptable manufacturing controls.
• Controlled-substance handling procedures.
• A compliant distribution structure.
• Product quality and stability.
• Packaging and labeling suitable for a high-risk drug.
• A REMS or shared-REMS arrangement where required.

The existence of a REMS did not guarantee that Jazz could block FDA approval indefinitely. Patent and regulatory barriers operated through separate legal mechanisms.

Which companies challenged Xyrem’s patent estate?

Xyrem faced challenges from multiple generic-drug companies over time. Publicly reported disputes and regulatory developments involved companies including Roxane Laboratories, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Lupin, and other ANDA applicants.

These cases did not all involve the same patents or the same settlement terms. A settlement with one filer did not bind unrelated ANDA applicants unless the agreement or patent position had broader legal consequences.

The competitive landscape included three possible entry models:

Entry model	Effect on Jazz
First generic launch	Immediate price and volume pressure
Multiple generic launch	Faster erosion of branded share and net price
Authorized generic	Jazz or its commercial partner retains some generic economics
Delayed negotiated launch	Preserves branded revenue until an agreed date

What was the revenue exposure from generic sodium oxybate?

Xyrem was one of Jazz’s largest products during the period of the Roxane litigation. The product generated substantial annual revenue, making patent settlements financially significant.

The principal exposure from generic entry included:

• Lower net price.
• Conversion of prescriptions to generic sodium oxybate.
• Payer-mandated substitution.
• Loss of pharmacy and patient retention.
• Reduced negotiating leverage with insurers.
• Erosion of revenue from related narcolepsy products.

Jazz mitigated part of this exposure through Xywav, a lower-sodium oxybate product with separate patent and regulatory positioning. Xywav’s launch provided a lifecycle-management strategy, although it did not remove the risk of generic substitution for Xyrem.

What is the current litigation status of 2:15-cv-01360?

The Roxane action is closed. It did not produce a reported final trial decision establishing infringement or invalidity of the asserted Xyrem patents.

The case is therefore relevant for:

• Historical analysis of Jazz’s Xyrem patent strategy.
• Hatch-Waxman settlement analysis.
• Assessment of controlled-distribution patent claims.
• Generic-entry timing.
• Comparison with later sodium oxybate litigation.
• Evaluation of Jazz’s lifecycle-management strategy.

It is not an active source of injunction risk against Roxane based on the public docket.

How does the Roxane case compare with later Xyrem patent disputes?

The Roxane case is best understood as an early negotiated resolution in the broader Xyrem patent cycle. Later disputes tested additional patents, later-issued claims, and different generic applicants.

Issue	Roxane case	Later Xyrem disputes
Product	Generic sodium oxybate	Generic sodium oxybate or related oxybate products
Main legal setting	Hatch-Waxman ANDA litigation	Hatch-Waxman litigation and follow-on patent disputes
Key technology	Controlled distribution and safe-use system	Distribution, formulation, dosing, and use claims
Public merits ruling	No reported final merits judgment	Varied by case
Commercial effect	Negotiated delay or resolution	Broader assessment of generic-entry timing
Biosimilar relevance	None	None

The absence of a merits judgment in the Roxane action limits its precedential value. The case’s commercial importance came from settlement leverage and the potential to delay generic competition while Jazz maintained Xyrem revenue.

Key Takeaways

• Jazz sued Roxane in Delaware after Roxane filed an ANDA for generic sodium oxybate.
• The case involved Paragraph IV challenges to Xyrem-related patents.
• Jazz’s principal asserted protection concerned controlled distribution, restricted access, and administration methods.
• The case ended through confidential settlement and dismissal.
• No public final judgment established infringement, patent validity, or patent invalidity.
• The dispute involved a generic drug, not a biosimilar.
• The case illustrates the limits and value of REMS-related and distribution-system patents in Hatch-Waxman litigation.
• Generic-entry risk remained dependent on other ANDA filers, later patent challenges, settlement terms, FDA approval, and commercial launch strategy.
• Xywav provided Jazz with a lifecycle-management product as Xyrem generic risk increased.
• The Roxane docket is closed and does not represent an active litigation barrier.

FAQs About Jazz Pharmaceuticals v. Roxane Laboratories

Did Roxane launch generic Xyrem after the lawsuit?

The public litigation record does not establish a Roxane commercial launch date. The action ended by settlement, and the agreement’s operative commercial terms were not publicly disclosed in the docket.

Was U.S. Patent No. 8,731,963 invalidated in the Roxane case?

No reported final decision in the Roxane action invalidated U.S. Patent No. 8,731,963. The case ended without a public merits judgment.

Did Jazz’s REMS block FDA approval of generic sodium oxybate?

No. REMS requirements and patent rights are separate. A generic applicant still had to satisfy FDA approval requirements, while Jazz had to enforce its patent rights through the Hatch-Waxman process.

Did the Roxane settlement include a payment from Jazz?

The public docket does not establish the financial terms of the settlement. Confidential Hatch-Waxman settlement agreements may include commercial provisions that are not disclosed in the dismissal order.

Was Xywav covered by the same patents asserted against Roxane?

Not necessarily. Xywav has a different formulation and separate patent and regulatory profile. Patent coverage must be assessed by product, claim scope, Orange Book listing, and the specific ANDA or NDA at issue.

References

1. U.S. District Court for the District of Delaware. (2015-2017). Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., No. 2:15-cv-01360. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2024). Xyrem (sodium oxybate) prescribing information and risk evaluation and mitigation strategy materials.

4. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 8,731,963, methods and systems for controlled distribution of sodium oxybate.

5. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 8,772,306, controlled distribution system and method.

6. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 6,780,889, sodium oxybate pharmaceutical compositions and methods.

7. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 7,668,730, methods of treating narcolepsy with sodium oxybate.